# Sekar Kathiresan
قسمت های برتر پادکست
به روز شده:
sekar kathiresan, M.D. is a physician-geneticist who is co-founder and chief executive officer of Verve Therapeutics. He is also a member of the company’s board of directors. Verve is developing therapies to safely edit the adult genome and confer lifelong protection from cardiovascular disease.
Kathiresan and Topol on Genomics of Heart Disease
Eric Topol speaks with Sekar Kathiresan about cardiovascular genomics, why 'DNA isn't destiny,' and why we still have heart attacks in spite of statins.
Episode 07 Dr. Sekar Kathiresan
Dr. Sekar Kathiresan. Genetic Mapping for Blood Lipids and Risk for Myocardial Infarction: What Have We Learned? Recorded 2011-03-07.
Sekar Kathiresan, MD: Pioneering Single Dose Medications to Cure Cardiovascular Disease
In this conversation, Daniel Belkin and Mitch Belkin speak with Sekar Kathiresan, MD, about using gene editing medications to treat cardiovascular disease. We discuss Dr. Kathiresan’s company Verve Therapeutics, which has pioneered a lipid nanoparticle delivery system of a CRISPR-based gene editing…
Circulation January 16, 2018 Issue
Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore. This week's feature paper takes a deep dive into nitric …
Single-course gene editing for cardiovascular disease, Sekar Kathiresan, Co-Founder & CEO, Verve Tx
Synopsis:
Sekar Kathiresan is the Co-Founder, CEO and Board Member of Verve Therapeutics, a clinical-stage biotechnology company developing gene editing medicines to treat patients with cardiovascular disease. Sekar discusses Verve’s work developing single-course, in vivo liver-directed gene editi…
Gene editing's next act
Gene editing’s therapeutic application has transitioned from hypothetical to reality, marked by the recent approval of a CRISPR-based therapy for sickle cell and beta thalassemia. In the wake of these developments, new biotech companies are springing up spurred by advancements that redefine what co…
🧬 Barry Ticho - Part 4 | Founding Verve Therapeutics Over Breakfast | Gene Editing for Cardiovascular Disease | Leadership Lessons From a First-Time Founder | Stoke’s Vision for RNA-Based Medicines
The Biotech Startups Podcast, brought to you by Excedr—empowering life science startups with founder-friendly equipment leasing to fast-track R&D and drive commercialization success.
Know someone in need of lab equipment? Join Excedr’s referral program: Give your friends $1,000 and earn $1,000 for…
The 'Big Beautiful Bill' and Other News
Howie and Harlan discuss health and healthcare issues making headlines, including public attitudes toward the Medicaid cuts in the budget bill making its way through Congress, a one-time gene therapy that could cure high cholesterol, "ambient" AI in the exam room, and the replacement of the the CDC…
The 'Big Beautiful Bill' and Other News
Howie and Harlan discuss health and healthcare issues making headlines, including public attitudes toward the Medicaid cuts in the budget bill making its way through Congress, a one-time gene therapy that could cure high cholesterol, "ambient" AI in the exam room, and the replacement of the the CDC…
Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan
In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about one of the boldest ideas in modern medicine: using one-time gene editing to permanently lower cholesterol and prevent heart disease.
Dr. Kathiresan shares…
موتور جستجوی پادکست
می توانید از وب سایت ما برای جستجوی پادکست های3,821,606و قسمت های195,390,899بر اساس افراد، مکان ها یا موضوعات استفاده کنید.
If I have seen further than others, it is by listening to podcasts and standing upon the shoulders of
giants.
‐ Isaac "Llamacorn" Newton
ویرایش
از کمک شما برای بروز نگهداشتن پایگاهدادههای پادکست سپاسگزاریم
